Treatment of thrombotic-occlusive diseases: cerebral thrombosis (w/in 5 days after onset of symptoms & w/o haemorrhage detectable by CT scan), peripheral arterial-venous occlusion (w/in 10 days after onset of symptoms).
Cerebral thrombosis 60,000 IU once daily for 7 days. Peripheral arterial-venous occlusion 60,000-240,000 IU on 1st day of treatment followed by tapered doses for 7 days.
Intracranial hemorrhage, hemoptysis, retroperitoneal hemorrhage; aneurysm; serious disturbance of consciousness; recent (in the last 2 mth) intracranial or spinal surgery or w/ such injury. Atrial fibrillation (particularly w/ mitral stenosis), infective endocarditis, old MI, patients w/ prosthetic valve; patients w/ neurological signs & symptoms of stroke w/c became complete instantaneously.
Hemorrhagic cerebral infarction may occur. Avoid in patients w/ a possibility of cerebral embolism or w/ a risk of bleeding. Monitor frequently hematologic indices eg, prothrombin time & bleeding time. W/draw immediately if intracerebral hemorrhage is suspected. Patients w/ hemorrhage or possible hemorrhage. History of hypersensitivity to urokinase or tissue culture urokinase. Patients w/ intractable hypocoagulopathy, coagulation factor deficiency, thrombocytopaenia. Concomitant anticoagulant treatment. Serious hepatic or renal disturbances. Pregnancy & lactation. Childn. Elderly.
Sign Out
